Friday, March 13, 2026
26.2
C
Bengaluru
Hot topics
The Rise and Fall of A.H. Robins Company: A Tale of Innovation Marred by One Acquisition
A.H. Robins Company was a formidable name in the...
Sales Force Strategy in the Digital World
Does Your Company Have a Well Thought-out Strategy on...
The Ethics Curve
K. Hariram reports on the OPPI 50th Annual General Meeting held in Mumbai on October 21. The report also features photos from the conference. Other topics covered include the role of emotions in pharma marketing, the importance in preparing much before-hand for the next level of your pharma career and the concept of the "tipping point" and its relevance for pharma marketing.
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
IMS Health Market Reflection Report for July 2016
The Indian Pharmaceutical Market (IPM) was valued atRs. 10,025 crores in the month of July 2016 clocking a 14.7% growth over same period last year (SPLY). This was the first time ever the market crossed the 10,000 crore mark in a single month.
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
Hot topics
Ashok Nair, Managing Director of Abbott India in Conversation with MedicinMan
Ashok Nair began his career as a Medical Rep...
IQVIA Sponsors Race for 7 to Commemorate World Rare Disease Day
“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention."
72nd Republic Day: What’s the Road Ahead for Indian Pharma?
“We are getting too happy, for too little”: these...
Is Pharma’s Business Model like McDonald’s? ...
Is Pharma’s business model like McDonald’s? Doing things over & over again without innovation?
McDonald’s is famous for its Hamburger University, a training facility at the McDonald’s Corporation global headquarters in Chicago, Illinois. It instructs high-potential restaurant managers in restaurant management.
More than 5,000 students attend Hamburger University each year and over 275,000 people have graduated with a degree in Hamburgerology.
Sound familiar? Pharma’s training has been on similar lines – hire people continuously and put them through the grind of mugging up essentials of drugs for diseases that the particular company sells.
While the McDonald’s model is ideal for its business of replication, it has outlived its utility in healthcare and drug companies are in danger of being reduced to mere suppliers of drugs to new digital platform businesses unless they learn to innovate.
Unmasking the Ethics of PCD Pharma Cos and the Incentives of Luxury Cars
🎁 The Diwali Dazzle: A Gilded Distraction?
In October 2025,...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
Newsletter
Get important news delivered directly to your inbox and stay connected!